Recent data and the FDA approval of tirzepatide have generated a lot excitement in the medical community about the role of this agent in the treatment of type 2 diabetes and obesity. In this podcast, CMHC Co-Chair Dr. Anne Peters, Professor of Medicine at the University of Southern California in LA, discusses the clinical implications of this agent and its potential role now and going forward.